C2N Diagnostics’ PrecivityAD2™ Blood Test Receives MHRA Medical Device Certification in the United Kingdom

Contributed by: Business Wire

Logo

Tags

Neurology

Biotechnology

Medical Supplies

General Health

Health

Medical Devices

Clinical Trials

Other Health

MHRA Medical Device Certification

More Like This

C₂N Diagnostics, LLC Announces Investment From Eisai Inc.

PR Newswire associated0

ALZHEIMER'S DISEASE BLOOD TESTS COULD IMPROVE DIAGNOSIS IN PRIMARY CARE, SPEED RECRUITING FOR RESEARCH & REDUCE WAIT TIMES

PR Newswire associated0

Diadem Unveils Novel Findings on Early Alzheimer's Disease Detection Using p53-Specific Antibody at CTAD 2024

Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

Dementia Mission Competition Selects Four Companies For Innovative Alzheimer’s Biomarker Study

PR Newswire associated0

Cumulus Neuroscience Presents Data at AD/PD™ 2025 Annual Meeting

PR Newswire associated0

Cumulus Neuroscience Presents Data at CTAD 2023 Annual Meeting

PR Newswire associated0

Cumulus Neuroscience Presents Data at AAIC 2024 Annual Meeting and Technology and Dementia Preconference